Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives

Journal of Medicinal Chemistry

Volumn 53, Issue 14, 2010, Pages 5129-5143

  De Los Ríos, Cristóbal ^a,b,d   Egea, Javier ^a   Marco Contelles, José ^b   León, Rafael ^a   Samadi, Abdelouahid ^b   Iriepa, Isabel ^d   Moraleda, Ignacio ^d   Gálvez, Enrique ^d   García, Antonio G ^a,c   López, Manuela G ^a   Villarroya, Mercedes ^a   Romero, Alejandro ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,8 NAPHTHYRIDINE DERIVATIVE; AMYLOID BETA PROTEIN[1-42]; ETHYL 5 AMINO 2 METHYL 6,7,8,9 TETRAHYDROBENZO[B][1,8]NAPHTHYRIDINE 3 CARBOXYLATE; ITH 4012; NEUROPROTECTIVE AGENT; OKADAIC ACID; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; HIPPOCAMPUS; HUMAN; HUMAN CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN DEPHOSPHORYLATION; RAT;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BUTYRYLCHOLINESTERASE; CALCIUM; CATALYTIC DOMAIN; CELL DEATH; CELL LINE, TUMOR; CHOLINESTERASE INHIBITORS; CYTOTOXINS; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; ELECTROPHORUS; GLUCOSE; HIPPOCAMPUS; HUMANS; ISOMERISM; MODELS, MOLECULAR; NAPHTHYRIDINES; NEUROPROTECTIVE AGENTS; OKADAIC ACID; OLIGOMYCINS; OXYGEN; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN PHOSPHATASE 2; RATS; ROTENONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954752031     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901902w     Document Type: Article

References (74)

1. Goedert, M.; Spillantini, M. G. A century of Alzheimer's disease Science 2006, 314, 777-781
2. Castro, A.; Martinez, A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors Curr. Pharm. Des. 2006, 12, 4377-4387
3. Gong, C. X.; Iqbal, K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease Curr. Med. Chem. 2008, 15, 2321-2328
4. Pratico, D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows Ann. N.Y. Acad. Sci. 2008, 1147, 70-78
5. Cummings, J. L. Treatment of Alzheimer's disease: current and future therapeutic approaches Rev. Neurol. Dis. 2004, 1, 60-69
6. Rafii, M. S.; Aisen, P. S. Recent developments in Alzheimer's disease therapeutics BMC Med. 2009, 7, 7
7. van Marum, R. J. Current and future therapy in Alzheimer's disease Fundam. Clin. Pharmacol. 2008, 22, 265-274
8. Fillit, H. M.; Doody, R. S.; Binaso, K.; Crooks, G. M.; Ferris, S. H.; Farlow, M. R.; Leifer, B.; Mills, C.; Minkoff, N.; Orland, B.; Reichman, W. E.; Salloway, S. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am. J. Geriatr. Pharmacother. 2006, 4 (Suppl. A), S9 - S24; quiz S25-S28.
9. Racchi, M.; Mazzucchelli, M.; Porrello, E.; Lanni, C.; Govoni, S. Acetylcholinesterase inhibitors: novel activities of old molecules Pharmacol. Res. 2004, 50, 441-451
10. Talesa, V. N. Acetylcholinesterase in Alzheimer's disease Mech. Ageing Dev. 2001, 122, 1961-1969
11. O'Neill, M. F. Difficult times for Alzheimer's treatments Drug Discovery Today 2005, 10, 1333-1335
12. Bullock, R.; Touchon, J.; Bergman, H.; Gambina, G.; He, Y.; Rapatz, G.; Nagel, J.; Lane, R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period Curr. Med. Res. Opin. 2005, 21, 1317-1327
13. Li, W.; Mak, M.; Jiang, H.; Wang, Q.; Pang, Y.; Chen, K.; Han, Y. Novel anti-Alzheimer's dimer bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets Neurotherapeutics 2009, 6, 187-201
14. Lorrio, S.; Sobrado, M.; Arias, E.; Roda, J. M.; Garcia, A. G.; Lopez, M. G. Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils J. Pharmacol. Exp. Ther. 2007, 322, 591-599
15. Arias, E.; Ales, E.; Gabilan, N. H.; Cano-Abad, M. F.; Villarroya, M.; Garcia, A. G.; Lopez, M. G. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors Neuropharmacology 2004, 46, 103-114
16. Melo, J. B.; Sousa, C.; Garcao, P.; Oliveira, C. R.; Agostinho, P. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons Eur. J. Neurosci. 2009, 29, 455-464
17. Noh, M. Y.; Koh, S. H.; Kim, Y.; Kim, H. Y.; Cho, G. W.; Kim, S. H. Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death J. Neurochem. 2009, 108, 1116-1125
18. Inestrosa, N. C.; Alvarez, A.; Perez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme Neuron 1996, 16, 881-891
19. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies Biochem. Pharmacol. 2003, 65, 407-416
20. Espinoza-Fonseca, L. M. The benefits of the multi-target approach in drug design and discovery Bioorg. Med. Chem. 2006, 14, 896-897
21. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372
22. Camps, P.; Formosa, X.; Galdeano, C.; Gomez, T.; Munoz-Torrero, D.; Scarpellini, M.; Viayna, E.; Badia, A.; Clos, M. V.; Camins, A.; Pallas, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Estelrich, J.; Lizondo, M.; Bidon-Chanal, A.; Luque, F. J. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation J. Med. Chem. 2008, 51, 3588-3598
23. Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; Recanatini, M.; Andrisano, V.; Rampa, A. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds Bioorg. Med. Chem. Lett. 2008, 18, 423-426
24. Camps, P.; Formosa, X.; Galdeano, C.; Munoz-Torrero, D.; Ramirez, L.; Gomez, E.; Isambert, N.; Lavilla, R.; Badia, A.; Clos, M. V.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodriguez-Franco, M. I.; Huertas, O.; Dafni, T.; Luque, F. J. Pyrano[3,2- c ]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds J. Med. Chem. 2009, 52, 5365-5379
25. Weinstock, M.; Kirschbaum-Slager, N.; Lazarovici, P.; Bejar, C.; Youdim, M. B.; Shoham, S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs Ann. N.Y. Acad. Sci. 2001, 939, 148-161
26. de los Rios, C.; Marco, J. L.; Carreiras, M. D.; Chinchon, P. M.; Garcia, A. G.; Villarroya, M. Novel tacrine derivatives that block neuronal calcium channels Bioorg. Med. Chem. 2002, 10, 2077-2088
27. Marco, J. L.; de los Rios, C.; Carreiras, M. C.; Banos, J. E.; Badia, A.; Vivas, N. M. Synthesis and acetylcholinesterase/butyrylcholinesterase inhibition activity of new tacrine-like analogues Bioorg. Med. Chem. 2001, 9, 727-732
28. Marco-Contelles, J.; Leon, R.; de Los Rios, C.; Guglietta, A.; Terencio, J.; Lopez, M. G.; Garcia, A. G.; Villarroya, M. Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease J. Med. Chem. 2006, 49, 7607-7610
29. Marco-Contelles, J.; Leon, R.; de los Rios, C.; Samadi, A.; Bartolini, M.; Andrisano, V.; Huertas, O.; Barril, X.; Luque, F. J.; Rodriguez-Franco, M. I.; Lopez, B.; Lopez, M. G.; Garcia, A. G.; Carreiras Mdo, C.; Villarroya, M. Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease J. Med. Chem. 2009, 52, 2724-2732
30. Summers, W. K.; Majovski, L. V.; Marsh, G. M.; Tachiki, K.; Kling, A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type N. Engl. J. Med. 1986, 315, 1241-1245
31. Mori, Y.; Mikala, G.; Varadi, G.; Kobayashi, T.; Koch, S.; Wakamori, M.; Schwartz, A. Molecular pharmacology of voltage-dependent calcium channels Jpn. J. Pharmacol. 1996, 72, 83-109
32. 2+ channel antagonists and neuroprotection from cerebral ischemia Eur. J. Pharmacol. 1998, 363, 1-15
33. Lukic-Panin, V.; Kamiya, T.; Zhang, H.; Hayashi, T.; Tsuchiya, A.; Sehara, Y.; Deguchi, K.; Yamashita, T.; Abe, K. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats Brain Res. 2007, 1176, 143-150
34. 2+ channels and nicotinic receptors Bioorg. Med. Chem. 2004, 12, 2199-2218
35. Orozco, C.; de Los Rios, C.; Arias, E.; Leon, R.; Garcia, A. G.; Marco, J. L.; Villarroya, M.; Lopez, M. G. ITH4012 (ethyl 5-amino-6,7,8,9-tetrahydro-2- methyl-4-phenylbenzol[1,8]naphthyridine-3-carboxylate), a novel acetylcholinesterase inhibitor with "calcium promotor" and neuroprotective properties J. Pharmacol. Exp. Ther. 2004, 310, 987-994
36. Abushanab, F. A.; Aly, F. M.; Wakefield, B. J. Synthesis of substituted nicotinamides from enamines derived from N, N -dimethylformamide dimethyl acetal Synthesis 1995, 923-925
37. Crey-Desbiolles, C.; Kotera, M. Synthesis of 3-deaza-3-nitro-2′- deoxyadenosine Bioorg. Med. Chem. 2006, 14, 1935-1941
38. Sunthankar, S. V.; Vaidya, S. D. Some reactions of 5-carbethoxy-3-cyano- 6-methyl-2-pyridone Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 1977, 15, 187-188
39. Minetti, P.; Tinti, M. O.; Carminati, P.; Castorina, M.; Di Cesare, M. A.; Di Serio, S.; Gallo, G.; Ghirardi, O.; Giorgi, F.; Giorgi, L.; Piersanti, G.; Bartoccini, F.; Tarzia, G. 2- n -Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9 H -purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization J. Med. Chem. 2005, 48, 6887-6896
40. Cheng, C. C.; Yan, S. J. The Friedlander synthesis of quinolines Org. React. 1982, 28, 37-201
41. Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Feather-Stone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 1961, 7, 88-95
42. Bourne, Y.; Grassi, J.; Bougis, P. E.; Marchot, P. Conformational flexibility of the acetylcholinesterase tetramer suggested by X-ray crystallography J. Biol. Chem. 1999, 274, 30370-30376
43. Ott, P.; Lustig, A.; Brodbeck, U.; Rosenbusch, J. P. Acetylcholinesterase from human erythrocytes membranes: dimers as functional units FEBS Lett. 1982, 138, 187-189
44. Liao, J.; Heider, H.; Sun, M. C.; Brodbeck, U. Different glycosylation in acetylcholinesterases from mammalian brain and erythrocytes J. Neurochem. 1992, 58, 1230-1238
45. Acheson, S. A.; Quinn, D. M. Anatomy of acetylcholinesterase catalysis: reaction dynamics analogy for human erythrocyte and electric eel enzymes Biochim. Biophys. Acta 1990, 1040, 199-205
46. Atack, J. R.; Yu, Q. S.; Soncrant, T. T.; Brossi, A.; Rapoport, S. I. Comparative inhibitory effects of various physostigmine analogs against acetyl- and butyrylcholinesterases J. Pharmacol. Exp. Ther. 1989, 249, 194-202
47. Andersen, R. A.; Aaraas, I.; Gaare, G.; Fonnum, F. Inhibition of acetylcholinesterase from different species by organophosphorus compounds, carbamates and methylsulphonyfluoride Gen. Pharmacol. 1977, 8, 331-334
48. Chan, S. L.; Shirachi, D. Y.; Bhargava, H. N.; Gardner, E.; Trevor, A. J. Purifcation and properties of multiple forms of brain acetylcholinesterase (EC 3.1.1.7) J. Neurochem. 1972, 19, 2747-2758
49. Rampa, A.; Bisi, A.; Belluti, F.; Gobbi, S.; Valenti, P.; Andrisano, V.; Cavrini, V.; Cavalli, A.; Recanatini, M. Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11 H -indeno-[1,2- b ]-quinolin-10-ylamine derivatives Bioorg. Med. Chem. 2000, 8, 497-506
50. Rosenberry, T. L.; Mallender, W. D.; Thomas, P. J.; Szegletes, T. A steric blockade model for inhibition of acetylcholinesterase by peripheral site ligands and substrate Chem.-Biol. Interact. 1999, 119-120, 85-97
51. Berridge, M. J. Calcium hypothesis of Alzheimer's disease. Pfluegers Arch. 2010, 459, 441 - 449.
52. Egea, J.; Rosa, A. O.; Cuadrado, A.; Garcia, A. G.; Lopez, M. G. Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress J. Neurochem. 2007, 102, 1842-1852
53. Koh, J. Y.; Choi, D. W. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay J. Neurosci. Methods 1987, 20, 83-90
54. Dodd, S.; Dean, O.; Copolov, D. L.; Malhi, G. S.; Berk, M. N -Acetylcysteine for antioxidant therapy: pharmacology and clinical utility Expert Opin. Biol. Ther. 2008, 8, 1955-1962
55. Arendt, T.; Holzer, M.; Bruckner, M. K.; Janke, C.; Gartner, U. The use of okadaic acid in vivo and the induction of molecular changes typical for Alzheimer's disease Neuroscience 1998, 85, 1337-1340
56. Sun, L.; Liu, S. Y.; Zhou, X. W.; Wang, X. C.; Liu, R.; Wang, Q.; Wang, J. Z. Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats Neuroscience 2003, 118, 1175-1182 (Pubitemid 36561203)
57. Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods 1986, 89, 271-277
58. Arias, E.; Gallego-Sandin, S.; Villarroya, M.; Garcia, A. G.; Lopez, M. G. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors J. Pharmacol. Exp. Ther. 2005, 315, 1346-1353
59. Sheppeck, J. E., 2nd; Gauss, C. M.; Chamberlin, A. R. Inhibition of the Ser-Thr phosphatases PP1 and PP2A by naturally occurring toxins Bioorg. Med. Chem. 1997, 5, 1739-1750
60. Harder, K. W.; Owen, P.; Wong, L. K.; Aebersold, R.; Clark-Lewis, I.; Jirik, F. R. Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase beta (HPTP beta) using synthetic phosphopeptides Biochem. J. 1994, 298 (Part 2) 395-401
61. Begum, N.; Ragolia, L. cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells J. Biol. Chem. 1996, 271, 31166-31171
62. Jarrett, J. T.; Berger, E. P.; Lansbury, P. T., Jr. The C-terminus of the beta protein is critical in amyloidogenesis Ann. N.Y. Acad. Sci. 1993, 695, 144-148
63. Pappolla, M. A.; Sos, M.; Omar, R. A.; Bick, R. J.; Hickson-Bick, D. L.; Reiter, R. J.; Efthimiopoulos, S.; Robakis, N. K. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide J. Neurosci. 1997, 17, 1683-1690
64. Masilamoni, J. G.; Jesudason, E. P.; Dhandayuthapani, S.; Ashok, B. S.; Vignesh, S.; Jebaraj, W. C.; Paul, S. F.; Jayakumar, R. The neuroprotective role of melatonin against amyloid beta peptide injected mice Free Radical Res. 2008, 42, 661-673
65. Sobrado, M.; Roda, J. M.; Lopez, M. G.; Egea, J.; Garcia, A. G. Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation Neurosci. Lett. 2004, 365, 132-136
66. Doody, R. S.; Gavrilova, S. I.; Sano, M.; Thomas, R. G.; Aisen, P. S.; Bachurin, S. O.; Seely, L.; Hung, D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study Lancet 2008, 372, 207-215
67. Bachurin, S. O.; Shevtsova, E. P.; Kireeva, E. G.; Oxenkrug, G. F.; Sablin, S. O. Mitochondria as a target for neurotoxins and neuroprotective agents Ann. N.Y. Acad. Sci. 2003, 993, 334-344; discussion 345-339
68. Lermontova, N. N.; Redkozubov, A. E.; Shevtsova, E. F.; Serkova, T. P.; Kireeva, E. G.; Bachurin, S. O. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels Bull. Exp. Biol. Med. 2001, 132, 1079-1083
69. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. Charmm, a program for macromolecular energy, minimization, and dynamics calculations J. Comput. Chem. 1983, 4, 187-217
70. Morreale, A.; Maseras, F.; Iriepa, I.; Galvez, E. Ligand-receptor interaction at the neural nicotinic acetylcholine binding site: a theoretical model J. Mol. Graphics Modell. 2002, 21, 111-118
71. Trott, O.; Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. Chem. 2010, 31, 455-461
72. Segel, I. H. Enzyme Kinetics; John Wiley: Toronto, Canada, 1975.
73. Egea, J.; Rosa, A. O.; Sobrado, M.; Gandia, L.; Lopez, M. G.; Garcia, A. G. Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in alpha7 nicotinic receptor knockout mice Neuroscience 2007, 145, 866-872
74. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 1983, 65, 55-63